Alumis Stock
Alumis is a clinical-stage biopharmaceutical company focused on developing oral precision therapies to transform the lives of patients with immune-mediated diseases. Its approach involves leveraging a precision analytics platform and deep expertise in precision medicine drug discovery, development, and immunology.
Founded: 2021
For more Alumis stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Martin Babler President, Chief Executive Officer, and Chairman |
| Mark Bradley Chief Development Officer |
| Jörn Drappa, MD, Ph.D. Chief Medical Officer |
| David Goldstein Chief Scientific Officer |
| Roy Hardiman Chief Business and Legal Officer |
| John Schroer Chief Financial Officer |
